Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

NCT03111992 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: PDR001
DRUG: CJM112
DRUG: LCL161

Sponsor

Novartis Pharmaceuticals